ASCO 2018: More Lung Cancer Patients Could Benefit From Immunotherapy Over Chemo – R & D Magazine
R & D Magazine |
ASCO 2018: More Lung Cancer Patients Could Benefit From Immunotherapy Over Chemo
R & D Magazine A new study demonstrates that immunotherapeutic agent pembrolizumab (Keytruda) is more effective than chemotherapy as a first-line treatment for most patients with a common type of lung cancer, regardless of patients' expression of PD-L1, a protein … |
